About
- About Shionogi
Sustainability
- Sustainability
Innovation
- Innovation
News

Investors
Careers
Contact

Europe

Home
News
Press Releases
Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation

Release

2015/08/03

Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation

About
Sustainability
Innovation
Investors
News
Careers

Worldwide
Report Side Effect
Terms of Use
Cookie Policy
Contact Us
Sitemap
Privacy Policy
References

© Shionogi B.V. 2024. All rights reserved. This website is owned by Shionogi B.V. Registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180. Registered address is Herengracht 464, 1017 CA, Amsterdam, the Netherlands.